Dsm Capital Partners Cut By $94.13 Million Its Starbucks (SBUX) Holding; Connor Clark & Lunn Investment Management LTD Has Raised Depomed (DEPO) Stake By $3.76 Million

June 18, 2018 - By Clifton Ray

Starbucks Corporation (NASDAQ:SBUX) Logo

Dsm Capital Partners Llc decreased Starbucks (SBUX) stake by 99.91% reported in 2018Q1 SEC filing. Dsm Capital Partners Llc sold 1.62M shares as Starbucks (SBUX)’s stock rose 1.31%. The Dsm Capital Partners Llc holds 1,430 shares with $83,000 value, down from 1.62M last quarter. Starbucks now has $78.90B valuation. The stock increased 0.11% or $0.06 during the last trading session, reaching $57.17. About 6.92M shares traded. Starbucks Corporation (NASDAQ:SBUX) has declined 7.92% since June 18, 2017 and is downtrending. It has underperformed by 20.49% the S&P500. Some Historical SBUX News: ; 27/04/2018 – Starbucks CEO says Philadelphia arrest protests have not hurt sales in April; 21/03/2018 – Starbucks Aims for More Mobile Orders; 29/05/2018 – ♫ Reuters Insider – VERBATIM: Starbucks founder defends decision to close stores; 27/04/2018 – Starbucks CEO says Philadelphia arrests did not hurt sales in March; 02/05/2018 – Starbucks: Further Details Will Be Provided in a Mutually Agreed Public Statement; 23/03/2018 – Starbucks: The Crystal Ball Frappucino Cometh — Barrons.com; 21/03/2018 – SBUX: CHINA IS FASTEST GROWING INTERNATIONAL MARKET FOR COMPANY; 21/03/2018 – STARBUCKS CORP – REITERATES COMMITMENT TO RETURN $15 BLN TO SHAREHOLDERS THROUGH NEXT THREE YEARS; 03/05/2018 – ABC7 News: .@ABC NEWS EXCLUSIVE: Two black men arrested at a Philadelphia Starbucks talk about the settlement they reached and; 16/04/2018 – Starbucks CEO apologizes for the arrest of 2 black men in Philadelphia

Connor Clark & Lunn Investment Management Ltd increased Depomed Inc (DEPO) stake by 53.63% reported in 2018Q1 SEC filing. Connor Clark & Lunn Investment Management Ltd acquired 627,320 shares as Depomed Inc (DEPO)’s stock declined 18.19%. The Connor Clark & Lunn Investment Management Ltd holds 1.80M shares with $11.84 million value, up from 1.17M last quarter. Depomed Inc now has $461.01M valuation. The stock increased 1.83% or $0.13 during the last trading session, reaching $7.25. About 625,156 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 38.98% since June 18, 2017 and is downtrending. It has underperformed by 51.55% the S&P500. Some Historical DEPO News: ; 10/05/2018 – DepoMed 1Q EPS 48c; 22/05/2018 – Starboard Has Reduced Depomed Stake to 4.3%; 20/04/2018 – DJ Depomed Inc, Inst Holders, 1Q 2018 (DEPO); 10/05/2018 – DepoMed 1Q Rev $128.4M; 02/04/2018 – DepoMed: Bukofzer Most Recently Served as Chief Medical Officer at Ocera Therapeutics Inc; 21/05/2018 – Depomed Forms Golden Cross: Technicals; 14/05/2018 – Allianz Global Holding in Depomed Published in Error; 02/04/2018 – DepoMed: Vetticaden to Remain With Company Through the End of April to Ensure a Smooth Transition; 09/05/2018 – Depomed Presenting at UBS Conference May 22; 10/05/2018 – DEPOMED – QTRLY ADJ SHR $0.28

Since March 7, 2018, it had 0 insider purchases, and 2 insider sales for $438,610 activity. 45,519 Depomed, Inc. (NASDAQ:DEPO) shares with value of $299,515 were sold by Gosling Matthew M.

Connor Clark & Lunn Investment Management Ltd decreased Stantec Inc. (NYSE:STN) stake by 22,600 shares to 80,100 valued at $1.98 million in 2018Q1. It also reduced Bellatrix Exploration Ltd. stake by 461,576 shares and now owns 521,756 shares. Walgreens Boots Alliance Inc was reduced too.

Among 14 analysts covering Depomed Inc (NASDAQ:DEPO), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Depomed Inc had 54 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Hold” rating by TheStreet given on Friday, October 16. Piper Jaffray initiated Depomed, Inc. (NASDAQ:DEPO) rating on Monday, February 8. Piper Jaffray has “Overweight” rating and $23 target. PiperJaffray downgraded the shares of DEPO in report on Wednesday, July 27 to “Neutral” rating. The company was maintained on Friday, November 10 by UBS. The rating was maintained by RBC Capital Markets on Friday, July 14 with “Hold”. Mizuho upgraded it to “Buy” rating and $24 target in Wednesday, November 9 report. On Monday, June 12 the stock rating was maintained by RBC Capital Markets with “Hold”. The stock of Depomed, Inc. (NASDAQ:DEPO) has “Buy” rating given on Wednesday, November 4 by Cantor Fitzgerald. Mizuho maintained the shares of DEPO in report on Monday, September 19 with “Buy” rating. The stock of Depomed, Inc. (NASDAQ:DEPO) has “Hold” rating given on Tuesday, August 8 by Mizuho.

More recent Depomed, Inc. (NASDAQ:DEPO) news were published by: Seekingalpha.com which released: “The Jury’s Still Out On Depomed” on May 21, 2018. Also Nasdaq.com published the news titled: “Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on June 07, 2018. Nasdaq.com‘s news article titled: “Depomed Announces the Appointment of Phillip B. Donenberg as Chief Financial Officer” with publication date: June 05, 2018 was also an interesting one.

Investors sentiment increased to 1.36 in Q1 2018. Its up 0.43, from 0.93 in 2017Q4. It improved, as 15 investors sold DEPO shares while 40 reduced holdings. 29 funds opened positions while 46 raised stakes. 60.75 million shares or 8.72% more from 55.87 million shares in 2017Q4 were reported. Alliancebernstein Lp holds 0% or 92,994 shares. Manufacturers Life Insur The reported 45,269 shares. Comml Bank Of Montreal Can has 0% invested in Depomed, Inc. (NASDAQ:DEPO). Assetmark holds 168 shares or 0% of its portfolio. Price T Rowe Assoc Inc Md stated it has 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). Goldman Sachs Grp stated it has 420,688 shares. Gamco Investors Et Al has 25,000 shares for 0% of their portfolio. Wells Fargo & Co Mn holds 0% or 594,266 shares in its portfolio. Systematic Financial Mgmt Lp reported 206,460 shares stake. Walleye Trading Ltd Llc holds 0% or 7,067 shares. Stone Ridge Asset Ltd Co reported 0.01% in Depomed, Inc. (NASDAQ:DEPO). Dekabank Deutsche Girozentrale holds 0% or 30,700 shares in its portfolio. Credit Suisse Ag holds 0% or 64,057 shares in its portfolio. Regions Fin Corp reported 273 shares stake. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO).

Investors sentiment decreased to 0.93 in 2018 Q1. Its down 0.12, from 1.05 in 2017Q4. It dropped, as 61 investors sold SBUX shares while 485 reduced holdings. 118 funds opened positions while 391 raised stakes. 955.12 million shares or 2.87% less from 983.38 million shares in 2017Q4 were reported. First Bancorporation holds 0.75% or 79,917 shares. Washington-based Zevenbergen Invests Limited Liability Com has invested 0.04% in Starbucks Corporation (NASDAQ:SBUX). Mitsubishi Ufj Secs Limited reported 410 shares. 67,258 were accumulated by Bender Robert & Associate. Ledyard National Bank owns 0.96% invested in Starbucks Corporation (NASDAQ:SBUX) for 137,029 shares. Swiss Bancorporation stated it has 5.19 million shares or 0.37% of all its holdings. Tci Wealth Advisors invested in 9,426 shares. Pacifica Cap Investments Lc, a California-based fund reported 522,636 shares. Carroll Fincl Assocs reported 6,651 shares or 0.04% of all its holdings. Salient Tru Company Lta, Texas-based fund reported 122,710 shares. Davidson Advsr has 1.1% invested in Starbucks Corporation (NASDAQ:SBUX) for 175,790 shares. Exxonmobil Investment Mngmt Tx reported 0.36% stake. Capital Intl Limited Ca reported 1.3% of its portfolio in Starbucks Corporation (NASDAQ:SBUX). Security Natl Trust holds 0.29% or 15,200 shares in its portfolio. Walter Keenan Fincl Consulting Mi Adv holds 0.95% or 37,865 shares in its portfolio.

Among 37 analysts covering Starbucks Corporation (NASDAQ:SBUX), 23 have Buy rating, 0 Sell and 14 Hold. Therefore 62% are positive. Starbucks Corporation had 108 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, July 28 by Stifel Nicolaus. The firm has “Buy” rating by UBS given on Friday, July 24. The stock has “Buy” rating by Longbow on Wednesday, September 21. The firm has “Buy” rating by Vetr given on Thursday, September 3. On Friday, July 28 the stock rating was maintained by Oppenheimer with “Buy”. Cowen & Co maintained Starbucks Corporation (NASDAQ:SBUX) rating on Friday, July 28. Cowen & Co has “Buy” rating and $6300 target. The rating was maintained by Robert W. Baird on Tuesday, June 5 with “Outperform”. Cowen & Co maintained Starbucks Corporation (NASDAQ:SBUX) on Friday, January 19 with “Buy” rating. The firm has “Outperform” rating by Robert W. Baird given on Friday, November 3. Mizuho maintained the shares of SBUX in report on Thursday, September 28 with “Buy” rating.

Analysts await Starbucks Corporation (NASDAQ:SBUX) to report earnings on July, 26. They expect $0.65 EPS, up 18.18% or $0.10 from last year’s $0.55 per share. SBUX’s profit will be $897.00 million for 21.99 P/E if the $0.65 EPS becomes a reality. After $0.53 actual EPS reported by Starbucks Corporation for the previous quarter, Wall Street now forecasts 22.64% EPS growth.

More notable recent Starbucks Corporation (NASDAQ:SBUX) news were published by: Seekingalpha.com which released: “Starbucks launches new prepaid Visa product” on June 11, 2018, also Nasdaq.com with their article: “Canadian Consumers Boycotting American Goods Is a Big Nothing Burger” published on June 15, 2018, Usatoday.com published: “Starbucks tops Apple in mobile payments: A Foolish Take” on June 16, 2018. More interesting news about Starbucks Corporation (NASDAQ:SBUX) were released by: Seekingalpha.com and their article: “Starbucks lifts coffee prices in the US” published on June 07, 2018 as well as Seekingalpha.com‘s news article titled: “Anti-bias training day at Starbucks” with publication date: May 29, 2018.

Since January 31, 2018, it had 0 buys, and 3 selling transactions for $13.62 million activity. 162,826 shares were sold by BURROWS CLIFFORD, worth $9.28M. Shares for $3.60M were sold by WEATHERUP CRAIG on Tuesday, March 13. ULLMAN MYRON E III also sold $740,851 worth of Starbucks Corporation (NASDAQ:SBUX) shares.

Depomed, Inc. (NASDAQ:DEPO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>